Usp22 inhibition combined with anti-PD1 induced a greater tumor regression and resulted in a higher percentage of CD8+ T cell infiltration compared with mice treated with anti-PD1 alone (Supplemental Figure 15, A–C). This evidence concerns the gene CD8A and neoplasm.